Octagon Capital Advisors LP 13F: Quarter-over-Quarter Portfolio Changes
Octagon Capital Advisors LP reported a disclosed portfolio value of approximately $1.1 billion in its latest SEC Form 13F-HR filing for Q2 2026, up 20.6% quarter on quarter. Over the quarter, the fund initiated 4 new positions, bought more shares in 4 holdings, trimmed 6 holdings, and exited 7 positions.
Octagon Capital Advisors LP's top buy was a new stake in Summit Therapeutics INC (SMMT) , equal to 1.7% of the disclosed portfolio. Its top sell was Centessa Pharmaceuticals PLC (CNTA) . The fund exited the position completely after it had accounted for 3.3% of the previous portfolio.
New PositionsQ2 2026
Securities disclosed for the first time in Q2 2026 that were not present in the prior 13F-HR filing.
| Company | Ticker | Initial Portfolio Weight | History |
|---|---|---|---|
| SUMMIT THERAPEUTICS INC | SMMT | 1.7% | Holders → |
| ADLAI NORTYE LTD | ANL | 1.0% | Holders → |
| FAETH THERAPEUTICS INC | SNSE | 0.8% | Holders → |
| GYRE THERAPEUTICS INC | GYRE | 0.6% | Holders → |
Top BuysQ2 2026
The fund's top buys among existing positions in Q2 2026. Ranked by portfolio-weight impact, with the percentage of additional shares shown separately.
| Company | Ticker | Portfolio Weight Change | More Shares | History |
|---|---|---|---|---|
| PHARVARIS N V | PHVS | +0.9% | +176.8% | Holders → |
| ABIVAX SA | ABVX | +3.8% | +46.7% | History → |
| DEFINIUM THERAPEUTICS INC | DFTX | +7.6% | +20.9% | History → |
| TAYSHA GENE THERAPIES INC | TSHA | +1.7% | +9.4% | History → |
Top SellsQ2 2026
The fund's top sells among positions it retained in Q2 2026. Ranked by portfolio-weight impact. Full exits are listed separately.
| Company | Ticker | Portfolio Weight Change | Shares Sold | History |
|---|---|---|---|---|
| TREVI THERAPEUTICS INC | TRVI | -1.4% | 78.8% | Holders → |
| CONTEXT THERAPEUTICS INC | CNTX | -1.4% | 41.9% | Holders → |
| PRECISION BIOSCIENCES INC | DTIL | -0.4% | 39.6% | Holders → |
| OCULAR THERAPEUTIX INC | OCUL | -1.1% | 34.5% | Holders → |
| KYMERA THERAPEUTICS INC | KYMR | -0.7% | 27.1% | History → |
| DIANTHUS THERAPEUTICS INC | DNTH | -1.6% | 5.4% | History → |
Full ExitsQ2 2026
Positions present in the prior 13F-HR filing that no longer appear in Q2 2026.
| Company | Ticker | Last-Reported Portfolio Weight |
|---|---|---|
| CENTESSA PHARMACEUTICALS PLC | CNTA | 3.3% |
| KALVISTA PHARMACEUTICALS | KALV | 3.2% |
| TERNS PHARMACEUTICALS INC | TERN | 3.1% |
| BRIDGEBIO ONCOLOGY THERAPEUT | BBOT | 0.7% |
| LEXEO THERAPEUTICS INC | LXEO | 0.7% |
| PERSPECTIVE THERAPEUTICS INC | CATX | 0.4% |
| EVOMMUNE INC | EVMN | 0.4% |
Net Portfolio Value ChangeQ2 2026
- $0.9BPrior quarter
- $1.1BCurrent quarter
- +$0.2BNet delta
- +20.6%% change
Methodology & FAQ
How Octagon Capital Advisors LP Quarterly Changes Are Computed
All deltas are sourced from sequential SEC Form 13F-HR filings for Octagon Capital Advisors LP: each row joins the most recent filing against the immediately preceding quarterly filing for the same fund. Share-count changes reflect reported trading activity, while portfolio weights can also move because of market price changes. Portfolio weights are normalized to exclude listed options for comparability. A complete description, including how confidential treatment filings are handled, is documented in the Methodology.
What stocks did Octagon Capital Advisors LP buy in Q2 2026?
In Q2 2026, Octagon Capital Advisors LP initiated 4 new positions (SUMMIT THERAPEUTICS INC (SMMT), ADLAI NORTYE LTD (ANL), FAETH THERAPEUTICS INC (SNSE), GYRE THERAPEUTICS INC (GYRE)); bought more shares of PHARVARIS N V (PHVS), ABIVAX SA (ABVX), DEFINIUM THERAPEUTICS INC (DFTX), TAYSHA GENE THERAPIES INC (TSHA).
What stocks did Octagon Capital Advisors LP sell in Q2 2026?
In Q2 2026, Octagon Capital Advisors LP fully sold 7 positions (CENTESSA PHARMACEUTICALS PLC (CNTA), KALVISTA PHARMACEUTICALS (KALV), TERNS PHARMACEUTICALS INC (TERN), BRIDGEBIO ONCOLOGY THERAPEUT (BBOT), LEXEO THERAPEUTICS INC (LXEO), PERSPECTIVE THERAPEUTICS INC (CATX), EVOMMUNE INC (EVMN)); reduced holdings in TREVI THERAPEUTICS INC (TRVI), CONTEXT THERAPEUTICS INC (CNTX), PRECISION BIOSCIENCES INC (DTIL), OCULAR THERAPEUTIX INC (OCUL), KYMERA THERAPEUTICS INC (KYMR) (the largest 5 of 6 reductions).
Which positions did Octagon Capital Advisors LP initiate in Q2 2026?
Octagon Capital Advisors LP established 4 new positions in Q2 2026: SUMMIT THERAPEUTICS INC (SMMT, 1.7%), ADLAI NORTYE LTD (ANL, 1.0%), FAETH THERAPEUTICS INC (SNSE, 0.8%), GYRE THERAPEUTICS INC (GYRE, 0.6%).
Which existing positions saw the largest allocation increases for Octagon Capital Advisors LP in Q2 2026?
Of 4 existing positions with share-count increases in Q2 2026, the largest were: PHARVARIS N V (PHVS, +0.9% weight, +176.8% shares), ABIVAX SA (ABVX, +3.8% weight, +46.7% shares), DEFINIUM THERAPEUTICS INC (DFTX, +7.6% weight, +20.9% shares), TAYSHA GENE THERAPIES INC (TSHA, +1.7% weight, +9.4% shares).
Which positions did Octagon Capital Advisors LP fully exit in Q2 2026?
Octagon Capital Advisors LP fully exited 7 positions in Q2 2026: CENTESSA PHARMACEUTICALS PLC (CNTA, last-reported weight 3.3%), KALVISTA PHARMACEUTICALS (KALV, last-reported weight 3.2%), TERNS PHARMACEUTICALS INC (TERN, last-reported weight 3.1%), BRIDGEBIO ONCOLOGY THERAPEUT (BBOT, last-reported weight 0.7%), LEXEO THERAPEUTICS INC (LXEO, last-reported weight 0.7%), PERSPECTIVE THERAPEUTICS INC (CATX, last-reported weight 0.4%), EVOMMUNE INC (EVMN, last-reported weight 0.4%).
Which existing positions saw the largest allocation reductions for Octagon Capital Advisors LP in Q2 2026?
Of 6 existing positions with share-count reductions in Q2 2026, the largest were: TREVI THERAPEUTICS INC (TRVI, -1.4% weight, -78.8% shares), CONTEXT THERAPEUTICS INC (CNTX, -1.4% weight, -41.9% shares), PRECISION BIOSCIENCES INC (DTIL, -0.4% weight, -39.6% shares), OCULAR THERAPEUTIX INC (OCUL, -1.1% weight, -34.5% shares), KYMERA THERAPEUTICS INC (KYMR, -0.7% weight, -27.1% shares), DIANTHUS THERAPEUTICS INC (DNTH, -1.6% weight, -5.4% shares).
Do quarter-over-quarter 13F allocation changes constitute explicit trading signals?
No. Quarter-over-quarter changes reflect a combination of active trading and market price movement. A weight increase can result from price appreciation alone, without the manager adding shares. Share-count delta is the cleaner indicator of explicit trading activity. All deltas on this page are sourced from sequential SEC Form 13F-HR filings.